CytoMed Therapeutics Ltd - GDTC

Detailed investor-level table based on 13F positions.

Shareholders (13F)

Quarter: Q2 2026 · Compare: Q1 2026
13D/13G major owners: Ownership tab.
Methodology: Market value and % of portfolio use SEC reported VALUE ($000). For PUT/CALL positions this reflects reported underlying exposure, not premium cash paid/received. Details.
Rows: 0
Investor History Status Shares held Market value ($000) % of portfolio Previous % Rank Change in shares % change in shares Source Date reported
Axiom Investment Management LLC History New 7,032 7 0.0% — 1 +7,032 New Q2 2026 Jul 30, 2026
UBS Group AG History Reduced 4,831 4 0.0% 0.0% 2 -1,351 -21.85% Q2 2026 Aug 13, 2026
XTX Topco Ltd History Closed out 0 0 — 0.0% — -10,136 -100.0% Q2 2026 Aug 14, 2026
OSAIC HOLDINGS, INC. History No change 21 0 — — — 0 0.0% Q2 2026 Aug 14, 2026